In vitro pharmacodynamics of AZD5206 against staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1062-1064

  Tam, Vincent H ^a,b   Chang, Kai Tai ^a   Yang, Zhen ^a   Newman, Joseph ^c   Hu, Ming ^b  

^a Department of Clinical Sciences and Administrationa ^*  (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZD 5206; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG SCREENING; GENE AMPLIFICATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; ORGANIC CHEMICALS; STAPHYLOCOCCAL INFECTIONS;

EID: 84872848202     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01208-12     Document Type: Article

References (9)

1. Gaynes R, Edwards Jr. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
2. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA. 2006. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:2626-2631.
4. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
5. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG. 2006. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
6. Singh R, Tam VH. 2011. Optimizing dosage to prevent emergence of resistance-lessons from in vitro models. Curr. Opin. Pharmacol. 11:453-456.
7. Mizunaga S, Kamiyama T, Fukuda Y, Takahata M, Mitsuyama J. 2005. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J. Antimicrob. Chemother. 56:91-96.
8. Craig WA, Bhavnani SM, Ambrose PG. 2004. The inoculum effect: Fact or artifact? Diagn. Microbiol. Infect. Dis. 50:229-230.
9. Singh R, Ledesma KR, Chang KT, Tam VH. 2010. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob. Agents Chemother. 54:4262-4268.